Brief: PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
29/10/2025 14:23
Oct 29 (Reuters) - PDS Biotechnology Corp PDSB.O: PDS BIOTECH TO SEEK EXPEDITED APPROVAL PATHWAY FOR PDS0101 IN HPV16-POSITIVE HEAD AND NECK CANCER Source text: ID:nGNXblX8Yj Further company coverage: PDSB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing